{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:55:06Z","timestamp":1789815306518,"version":"4.0.1"},"reference-count":8,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,10,19]],"date-time":"2004-10-19T00:00:00Z","timestamp":1098144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2004,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drugs are an important cause of serious rare blood dyscrasias. To estimate the proportion of drug\u2010related cases, we used data from the ongoing Berlin Case\u2010Control Surveillance Study. The analysis included a total of 171 cases. The number of cases in which a drug etiology was assessed as at least \u201cpossible\u201d was <jats:italic>n<\/jats:italic> = 29 (97%) for acute agranulocytosis, <jats:italic>n<\/jats:italic> = 4 (0.21%) for aplastic anemia, <jats:italic>n<\/jats:italic> = 8 (26%) for immune hemolytic anemia, <jats:italic>n<\/jats:italic> = 20 (25%) for immune thrombocytopenia, and <jats:italic>n<\/jats:italic> = 2 (20%) for thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome. Our analysis suggests that a substantial fraction of blood dyscrasias may be attributable to drug therapy. Am. J. Hematol. 77:316\u2013318, 2004. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.20176","type":"journal-article","created":{"date-parts":[[2004,10,19]],"date-time":"2004-10-19T19:56:09Z","timestamp":1098215769000},"page":"316-318","source":"Crossref","is-referenced-by-count":38,"title":["Proportion of drug\u2010related serious rare blood dyscrasias: Estimates from the Berlin Case\u2010Control Surveillance Study"],"prefix":"10.1002","volume":"77","author":[{"given":"Frank","family":"Andersohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Bronder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Klimpel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edeltraut","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,19]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.1996.tb01641.x","article-title":"Drugs in the aetiology of agranulocytosis and aplastic anaemia","volume":"60","author":"Kaufman DW","year":"1996","journal-title":"Eur J Haematol Suppl"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0609.1996.tb01639.x","article-title":"When should the clinician suspect a drug\u2010induced blood dyscrasia, and how should he proceed?","volume":"60","author":"Heimpel H","year":"1996","journal-title":"Eur J Haematol Suppl"},{"key":"e_1_2_1_4_2","first-page":"97","volume-title":"Aplastic anemia","author":"Heimpel H","year":"2000"},{"key":"e_1_2_1_5_2","volume-title":"WHO causality assessment method","author":"World Health Organisation"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.56.655.322"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2003.10.001"},{"key":"e_1_2_1_8_2","first-page":"117","volume-title":"Aplastic anemia","author":"Marin P","year":"2000"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1947.x"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.20176","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.20176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T23:25:50Z","timestamp":1700263550000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.20176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,19]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["10.1002\/ajh.20176"],"URL":"https:\/\/doi.org\/10.1002\/ajh.20176","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,19]]}}}